A scientometric analysis of research on the role of NMDA receptor in the treatment of depression.
Frontiers in pharmacology January 1, 2024 Xulin Chen, Xian Wang, Caijuan Li et al. 7 citations
Over the past 20 years, research on NMDA receptors as targets for depression treatment has grown steadily, with 5,092 publications identified. The United States leads in collaborations, publications, and citations. Co-cited reference analysis revealed 15 main clusters. Recent hotspots include ketamine (an NMDA receptor antagonist) for treatment-resistant depression, oxidative stress, synaptic plasticity, and neuroplasticity-related factors such as brain-derived neurotrophic factor. While ketamine's application and mechanisms in major depressive disorder remain a hot topic, its side effects have spurred investigation into new rapid-acting antidepressants.